CYB5R3 functions as a tumor suppressor by inducing ER stress-mediated apoptosis in lung cancer cells via the PERK-ATF4 and IRE1α-JNK pathways
-
Published:2024-01-22
Issue:1
Volume:56
Page:235-249
-
ISSN:2092-6413
-
Container-title:Experimental & Molecular Medicine
-
language:en
-
Short-container-title:Exp Mol Med
Author:
Im Joo-YoungORCID, Kim Soo Jin, Park Jong-Lyul, Han Tae-Hee, Kim Woo-il, Kim Inhyub, Ko Bomin, Chun So-Young, Kang Mi-Jung, Kim Bo-Kyung, Jeon Sol A., Kim Seon-KyuORCID, Ryu Incheol, Kim Seon-YoungORCID, Nam Ki-Hoan, Hwang Inah, Ban Hyun Seung, Won Misun
Abstract
AbstractCytochrome b5 reductase 3 (CYB5R3) is involved in various cellular metabolic processes, including fatty acid synthesis and drug metabolism. However, the role of CYB5R3 in cancer development remains poorly understood. Here, we show that CYB5R3 expression is downregulated in human lung cancer cell lines and tissues. Adenoviral overexpression of CYB5R3 suppresses lung cancer cell growth in vitro and in vivo. However, CYB5R3 deficiency promotes tumorigenesis and metastasis in mouse models. Transcriptome analysis revealed that apoptosis- and endoplasmic reticulum (ER) stress-related genes are upregulated in CYB5R3-overexpressing lung cancer cells. Metabolomic analysis revealed that CYB5R3 overexpression increased the production of nicotinamide adenine dinucleotide (NAD+) and oxidized glutathione (GSSG). Ectopic CYB5R3 is mainly localized in the ER, where CYB5R3-dependent ER stress signaling is induced via activation of protein kinase RNA-like ER kinase (PERK) and inositol-requiring enzyme 1 alpha (IRE1α). Moreover, NAD+ activates poly (ADP-ribose) polymerase16 (PARP16), an ER-resident protein, to promote ADP-ribosylation of PERK and IRE1α and induce ER stress. In addition, CYB5R3 induces the generation of reactive oxygen species and caspase-9-dependent intrinsic cell death. Our findings highlight the importance of CYB5R3 as a tumor suppressor for the development of CYB5R3-based therapeutics for lung cancer.
Funder
Korea Research Institute of Bioscience and Biotechnology Korea Institute for Advancement of Technology
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424, https://doi.org/10.3322/caac.21492 (2018). 2. Osmani, L., Askin, F., Gabrielson, E. & Li, Q. K. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin. Cancer Biol. 52, 103–9, https://doi.org/10.1016/j.semcancer.2017.11.019 (2018). 3. Pikor, L. A., Ramnarine, V. R., Lam, S. & Lam, W. L. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 82, 179–89, https://doi.org/10.1016/j.lungcan.2013.07.025 (2013). 4. George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretic, L. & Kong, G. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53, https://doi.org/10.1038/nature14664 (2015). 5. Lockwood, W. W., Wilson, I. M., Coe, B. P., Chari, R., Pikor, L. A. & Thu, K. L. et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One 7, e37775, https://doi.org/10.1371/journal.pone.0037775 (2012).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|